AstraZeneca enters definitive agreement to acquire Amolyt Pharma for $1.05 billion
AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. Under the terms of the agreement, AstraZeneca will acquire all of Amolyt Pharma’s outstanding shares for…